OKYO

OKYO Pharma Limited

1.46

Nov 02 • 3:58 PM ET -0.01 (-0.68%)

1.46

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology United Kingdom Micro NASD

Peers: ALDX OCS LENZ KALA TARS EYPT OCUL IRD HROW BLCO

Scroll to Statements

Index	-
Market Cap	76.62M
Enterprise Value	56.03M
Income	-8.95M
Sales	0.00M
Book/sh	0.24
Cash/sh	0.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 17, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.21
P/C	3.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.43
Current Ratio	2.43
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.19
EPS next Y	-0.41
EPS next Q	-0.04
EPS this Y	20.59%
EPS next Y	-200.00%
EPS next 5Y	-
EPS past 3/5Y	26.21% -116.82%
Sales past 3/5Y	- -
EPS Y/Y TTM	-39.90%
Sales Y/Y TTM	-
EPS Q/Q	-115.28%
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	-87.50% -

Insider Own	32.09%
Insider Trans	0.00%
Inst Own	20.10%
Inst Trans	0.68%
ROA	-72.60%
ROE	-263.78%
ROIC	-72.55%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.24%
SMA50	1.30%
SMA200	-9.35%
Trades

Shs Outstand	52.48M
Shs Float	35.64M
Short Float	0.22%
Short Ratio	1.16
Short Interest	0.08M
52W High	3.20 -54.37%
52W Low	1.26 15.43%
Volatility	7.37% 6.35%
ATR (14)	0.10
RSI (14)	51.77
Beta	0.03
Rel Volume	1.39
Avg Volume	66.07K
Volume	91,930

Perf Week	1.39%
Perf Month	-0.68%
Perf Quarter	-10.98%
Perf Half Y	-13.10%
Perf YTD	-29.47%
Perf Year	-46.72%
Perf 3Y	-9.88%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	1.47
Price	1.46
Change %	-0.68%

Consensus

Strong Buy

Avg. Price Target

$6.00

Implied Upside

+311.0%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Feb 20, 2026	Initiated	PPiper Sandler	Overweight	$7	+379.5%
Dec 08, 2025	Initiated	RB. Riley Securities	Buy	$5	+242.5%

Oct-06-26 08:30AM	OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug (Proactive)
07:00AM	OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
Sep-29-26 07:00AM	OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences (GlobeNewswire)
Sep-09-26 07:00AM	OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 (GlobeNewswire) -5.23%
Sep-08-26 07:00AM	OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
Jul-28-26 07:00AM	OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer (GlobeNewswire)
Jul-27-26 07:00AM	OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 (GlobeNewswire) +5.81%
Jul-23-26 12:00PM	OKYO Pharma Announces Purchase of Shares by Director (GlobeNewswire)
07:00AM	OKYO Pharma Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire)
Jul-22-26 12:00PM	OKYO Pharma Announces Purchase of Shares by Chairman (GlobeNewswire) +5.56%
10:00AM	OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director (GlobeNewswire)
07:00AM	OKYO Pharma Announces Purchase of Shares by Chief Medical Officer (GlobeNewswire)
Jul-21-26 09:00AM	OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.11%
07:00AM	OKYO Pharma Announces Purchase of Shares by Chairman (GlobeNewswire)
Jul-20-26 08:33AM	OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans (Proactive)
07:00AM	Loading…
07:00AM	OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans (GlobeNewswire)
Jul-11-26 10:00AM	OKYO Pharma advances toward Phase 3 FDA trial - ICYMI (Proactive)
Jul-08-26 08:33AM	OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain (Proactive) -5.14%
08:12AM	Nasdaq bucks market selloff as US-Iran tensions push oil higher (Proactive)
08:12AM	Dow and Nasdaq lose more ground as Trump says Iran ceasefire 'over' (Proactive)
07:00AM	OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain (GlobeNewswire)
Jul-07-26 11:18AM	OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain (Proactive) +8.70%
07:00AM	OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium (GlobeNewswire)
May-23-26 08:00AM	OKYO Pharma expands scientific advisory board with cornea expert - ICYMI (Proactive)
May-19-26 11:02AM	OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment (Proactive)
09:58AM	OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board (Proactive)
07:00AM	OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD (GlobeNewswire)
Apr-29-26 07:00AM	OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May (GlobeNewswire)
Apr-07-26 08:40AM	OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026 (Proactive)
08:40AM	OKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentation (Proactive)
07:00AM	Loading…
07:00AM	OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting (GlobeNewswire)
Mar-19-26 12:00PM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire)
10:00AM	OKYO Pharma Announces Director Acquires Shares (GlobeNewswire)
07:00AM	OKYO Pharma Announces Chief Development Officer and Director Acquires Shares (GlobeNewswire)
Mar-18-26 09:02AM	OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial (Proactive)
07:00AM	OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain (GlobeNewswire)
Feb-23-26 04:15PM	Dow Jones sheds more than 800 points on Trump's latest tariff threat (Proactive)
03:30PM	Nasdaq, Dow Jones start the week lower as Trump resets tariffs (Proactive)
11:56AM	OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 (Proactive)
11:00AM	OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress (GlobeNewswire)
Feb-17-26 04:20PM	Nasdaq posts slim gain in calm trade as Wall Street inches up (Proactive)
03:49PM	Nasdaq climbs alongside Dow and S&P 500 in afternoon trading (Proactive)
12:56PM	OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain (Proactive)
Feb-13-26 08:50AM	OKYO Pharma prices $20M offering to fund late-stage eye drug trial (Proactive) -19.35%
Feb-12-26 10:20PM	OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares (GlobeNewswire) +11.28%
04:01PM	OKYO Pharma Announces Public Offering of Ordinary Shares (GlobeNewswire)
Feb-11-26 11:03AM	OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering (Proactive) -6.70%
10:09AM	OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners (GlobeNewswire)
Feb-10-26 09:36AM	OKYO Pharma appoints Flavio Mantelli as chief medical officer (Proactive) +5.03%
08:00AM	OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer (GlobeNewswire)
Jan-30-26 11:30AM	OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting (GlobeNewswire)
Jan-28-26 01:18PM	OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial (Proactive)
07:40AM	OKYO Pharma Announces Successful Type C Meeting with the FDA (GlobeNewswire)
Jan-23-26 07:00AM	FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain (GlobeNewswire) -6.33%
Jan-05-26 07:00AM	OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer (GlobeNewswire) +7.62%
Dec-19-25 07:00AM	OKYO Pharma to Ring the Opening Bell at Nasdaq (GlobeNewswire) +8.56%
Dec-15-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) -8.25%
Dec-11-25 08:30AM	OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain (GlobeNewswire) +6.93%
Dec-03-25 07:00AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) -5.77%
Nov-21-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire) +10.99%
Nov-18-25 08:30AM	OKYO Pharma to Present at OIS XV in San Diego (GlobeNewswire)
Oct-29-25 07:00AM	OKYO Pharma to Present at BIO-Europe 2025 in Vienna (GlobeNewswire) +6.67%
Oct-16-25 08:30AM	OKYO Pharma Announces Chairman and Founder Acquires Shares (GlobeNewswire)
Sep-22-25 08:30AM	OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain (GlobeNewswire) +13.64%
Jul-17-25 09:00AM	OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
05:47AM	OKYO reports top-line data from neuropathic corneal pain therapy trial (Clinical Trials Arena)
Jul-16-25 09:21AM	OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire) +7.64%
Jun-11-25 10:05AM	Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited (ACCESSWIRE) +12.56%
08:30AM	OKYO Pharma to Present at the Bio International Convention (GlobeNewswire)
May-19-25 07:00AM	OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit (GlobeNewswire) +7.91%
May-01-25 07:00AM	FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain (GlobeNewswire)
Apr-30-25 07:00AM	OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire)
Mar-31-25 08:00AM	OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod (GlobeNewswire) -5.93%
Mar-10-25 08:30AM	OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain (GlobeNewswire)
Feb-12-25 07:00AM	OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod (GlobeNewswire)
Jan-31-25 07:00AM	OKYO Pharma Announces Chairman and CEO Acquire Shares (GlobeNewswire)
Jan-30-25 09:45AM	Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited (ACCESSWIRE)
Jan-29-25 08:00AM	OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter (GlobeNewswire)
Jan-23-25 07:11AM	Okyo Pharma receives $1.4M in non-dilutive financing (TipRanks)
Jan-22-25 07:00AM	OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding (GlobeNewswire)
Nov-26-24 07:00AM	OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference (GlobeNewswire)
Nov-15-24 09:00AM	MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-30-24 07:00AM	OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference (GlobeNewswire)
Oct-23-24 07:00AM	OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain (GlobeNewswire) +19.42%
Oct-17-24 07:27AM	OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug (TipRanks)
Oct-16-24 07:00AM	OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain (GlobeNewswire)
Sep-10-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire) +6.80%
Sep-05-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-27-24 07:00AM	OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease (GlobeNewswire) +14.72%
Aug-23-24 09:00AM	OKYO Pharma CEO Interview to Air on Bloomberg TV (GlobeNewswire)
09:00AM	OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-21-24 07:00AM	OKYO Pharma Announces Chairman Acquires Shares (GlobeNewswire)
Aug-15-24 12:13PM	OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-06-24 07:00AM	OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use (GlobeNewswire) +5.26%
Jul-11-24 07:00AM	OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 (GlobeNewswire) +25.64%
Jul-10-24 07:00AM	OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease (GlobeNewswire)
Jun-26-24 10:29AM	Promising Developments from OKYO Pharma on Dry Eye Disease and Neuropathic Pain Treatment (News Direct)
May-24-24 03:07PM	OKYO Pharma Bullish Thesis (Insider Monkey) -11.06%
May-08-24 07:00AM	OKYO Pharma Announces Participation in May 2024 Investor Conferences (GlobeNewswire)

Show Previous News

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

CEO & Executive DirectorMr. Robert J. Dempsey M.B.A.

Chief Financial OfficerMs. Keeren Shah

Chief Scientific OfficerDr. Rajkumar Patil Ph.D.

Chief Development Officer & DirectorDr. Gary S. Jacob Ph.D.

Ph.D.Dr. Flavio Mantelli M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OKYO

OKYO Pharma Limited

Upgrade your Finviz experience